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Abstract
Background: This study aimed to evaluate the efficacy of a high dose of oral tegafur-uracil (400 mg/m2) plus
leucovorin with preoperative chemoradiation of locally advanced rectal cancer and to explore the impact of
polymorphisms of cytochrome P 2A6 (CYP2A6), uridine monophosphate synthetase (UMPS), and ATP-binding
cassette B1 (ABCB1) on clinical outcome.
Methods: Patients with cT3 or cT4 rectal cancer were enrolled and were given tegafur-uracil 400 mg/m2/day and
leucovorin 90 mg/m2/day for 7 days a week during preoperative chemoradiation (50.4 Gy/28 fractions) in this phase
II trial. Primary endpoint was pathologic complete response rate, and the secondary endpoint was to explore the
association between clinical outcomes and genetic polymorphisms CYP2A6 (*4, *7, *9 and *10), UMPS G638C, and
three ABCB1 genotypes (C1236T, C3435T, and G2677T).
Results: Ninety-one patients were given study treatment, and 90 underwent surgery. Pathologic complete response was
noted in 10 patients (11.1%). There was no grade 4 or 5 toxicity; 20 (22.0%) experienced grade 3 toxicities, including
diarrhea (10, 11.0%), abdominal pain (2, 2.2%), and anemia (2, 2.2%). Relapse-free survival and overall survival at
5 years were 88.6% and 94.2%, respectively. Patients with the UMPS 638 CC genotype experienced
significantly more frequent grade 2 or 3 diarrhea (p for trend = 0.018).
Conclusions: Preoperative chemoradiation with tegafur-uracil 400 mg/m2/day with leucovorin was feasible,
but did not meet the expected pathologic complete response rate. The UMPS 638 CC genotype might be a
candidate biomarker predicting toxicity in patients receiving tegafur-uracil/leucovorin-based preoperative
chemoradiation for locally advanced rectal cancer.
Trial registration: ISRCTN11812525, registered on 25 July 2016. Retrospectively registered.
Keywords: Rectal neoplasms, Chemoradiotherapy, Tegafur, Uridine monophosphate synthetase
* Correspondence: ksy@ncc.re.kr
2Department of Laboratory Medicine, Research Institute and Hospital,
National Cancer Center, 323 Ilsan-ro, Ilsandong-gu, Goyang-si, Gyeonggi-do
10408, Republic of Korea
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Kim et al. Radiation Oncology  (2017) 12:62 
DOI 10.1186/s13014-017-0800-5
Introduction
Preoperative chemoradiation (CRT) with fluoropyrimidine
such as 5-fluorouracil (5-FU) or capecitabine was shown
to be effective in terms of reducing the risk of local recur-
rence of rectal cancer [1, 2], and has become the standard
treatment. Tegafur-uracil (UFT) is another oral fluoropyri-
midine that has shown similar efficacy to 5-FU as an adju-
vant treatment for colorectal cancer [3]. It has also been
tested as a preoperative CRT option for rectal cancer, but
the doses and schedules have varied [4]. In general, UFT
300–400 mg/m2/day plus leucovorin (LV) 25–75 mg/day
for 5 days a week at 45 Gy radiation (RT) for locally ad-
vanced rectal cancer was efficacious and tolerable [4]. This
combination produced comparable outcomes to 5-FU in
terms of toxicity profile and pathologic complete response
rate in a randomized trial, although the study was under-
powered due to incomplete accrual [5].
Many of the studies on UFT with CRT for rectal can-
cer were performed in a Caucasian population; however,
the gastrointestinal toxicity of tegafur-based drugs such
as UFT and S-1 is known to be more tolerable in Asian
patients compared to Caucasians [6, 7]. This trend has
not been fully explained by differences in pharmacokin-
etics or genetic polymorphisms.
On the premise of its favorable safety profile, increas-
ing the dose of tegafur could be a strategy to enhance
treatment efficacy in Asian patients. We obtained favor-
able results from a pilot preoperative CRT study with
continuous dosing of high-dose (400 mg/m2/day)
enteric-coated tegafur-uracil (UFT-E) and LV, which pro-
duced a pathologic complete response (pCR) rate of 22%
in 36 patients [8]. Based on these results, we aimed to
perform a phase II trial to evaluate the pCR rate and
toxicity profile of preoperative CRT with UFT-E and LV.
To identify patients who benefit most from CRT with
high-dose UFT-E with LV, individual difference in the
process of metabolism and excretion of tegafur should
be considered. CYP2A6 and UMPS have crucial role in
conversion of tegafur to active metabolite, and ABCB1
encodes P-glycoprotein that pumps toxic metabolites
out of gastrointestinal epithelium. With this phase II
trial, we also planned to analyze trial participants’ geno-
types for CYP2A6, UMPS, and ABCB1.
Methods
Patient eligibility
This study was designed as a single-center phase II trial
evaluating pCR of UFT-E and LV with RT before total
mesorectal excision (TME) of rectal cancer. Patients
were eligible if they satisfied the following criteria: age ≥
18 years; histologically confirmed adenocarcinoma of the
rectum located within 8 cm of the anal verge by digital
rectal exam; cT3-4 disease on magnetic resonance im-
aging (MRI)-based staging or rectal ultrasound; Eastern
Cooperative Oncology Group (ECOG) performance sta-
tus ≤ 2; adequate bone marrow, liver, and renal function.
Patients were excluded if baseline imaging studies in-
cluding computed tomography (CT) of chest, abdomen
and pelvis led to suspicion of distant metastases, or if
they had unresected synchronous colon cancer or a his-
tory of malignancy within 5 years before screening. The
protocol of this study was approved by the Institutional
Review Board of the National Cancer Center, Goyang,
Korea (the protocol number NCCCTS-08-358). This
study was conducted in accordance with the Declaration
of Helsinki and Good Clinical Practice guidelines.
Study treatment
CRT was started within 14 days after screening and
obtaining informed consent. UFT-E was given orally as
400 mg/m2 of tegafur divided into three daily doses
without drug holidays during RT. Since each package of
UFT-E contains 500 mg of granules that corresponded
to 100 mg of tegafur, the recommended dosing schedule
according to body surface area (BSA) was as follows:
BSA ≤ 1.37 m2: 2, 2, and 1 packages an hour after break-
fast, lunch and dinner, respectively; BSA 1.38 m2 – 1.62
m2: 2, 2, and 2 packages; BSA 1.63 m2 – 1.87 m2: 3, 2,
and 2 packages; and BSA ≥ 1.88 m2: 3, 3, and 2 packages.
Each dose of UFT-E was administered with 2 15-mg tab-
lets of LV, corresponding to a total daily dose of 90 mg.
Preoperative RT was delivered concurrently to the
whole pelvis at a dose of 45 Gy in 25 fractions, followed
by 5.4 Gy in a three-fraction boost to the primary tumor.
The details of RT simulation, beam weights, and the RT
field have been described previously [9]. Surgery was
planned within 6 ± 2 weeks of the completion of CRT.
TME was the first-choice surgical treatment, with the
final decision regarding the choice of surgical procedure
(abdominoperineal or anterior resection) made by the
surgeon with the approval of a multidisciplinary team.
Postoperative chemotherapy was administered at discre-
tion of the treating medical oncologist (SYK and JYB).
One of the following regimens was administered for 4
months: 4 cycles of Mayo regimen 5-FU/LV (5-FU 400
mg/m2 and LV 20 mg/m2 on days 1–5, every 4 weeks), 3
or 4 cycles of UFT-E/LV (UFT-E 300 mg/m2 and LV 90
mg/day on day 1–28, every 5 weeks), or 8 cycles of
FOLFOX-6 (oxaliplatin 85 mg/m2, LV 200 mg/m2, 5-FU
bolus 400 mg/m2 and 5-FU continuous infusion 2400 mg/
m2 for 46 h every 2 weeks).
Evaluation
Clinical T and N staging according to the American Joint
Committee on Cancer 7th staging system by MRI or rectal
ultrasound was recorded. The primary endpoint of this
study, pCR, was evaluated according to Dworak’s classifi-
cation [10] and the detailed procedure is described in our
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previous report [9]. A positive circumferential margin
(CRM) was defined as tumor within ≤ 1 mm. The second-
ary endpoints included safety of CRT, relapse-free survival
(RFS), overall survival (OS), and association of clinical out-
comes with pharmacogenetic profile. RFS was calculated
from the date of starting CRT to the date on which either
of recurrence, progression, or death was first observed, or
the date of last follow-up. OS was defined as from the date
of starting CRT to the date of death from any cause or last
follow-up. Safety outcomes were monitored according to
the National Cancer Institute Common Terminology
Criteria (NCI-CTC) scale, version 3.0.
Protocol amendment
From January to June 2009, 23 patients were enrolled.
Serious adverse events (admission due to toxicity) oc-
curred in 6 patients (26.1%) and RT was interrupted due
to grade 3 diarrhea in 2 patients. The unexpectedly high
incidence of toxicity led to protocol amendment in July
2009: UFT-E and LV dosing days were reduced from 7
days to 5 days per week during CRT.
Pharmacogenetic profiling
Genomic DNA was extracted from peripheral blood
drawn before treatment. We assessed the presence of gen-
etic variants of CYP2A6, UMPS and ABCB1 using direct
sequencing: CYP2A6*4 (whole deletion of CYP2A6),
CYP2A6*7 (6558T >G, rs5031016), CYP2A6*9 (-48T >G,
rs28399433), CYP2A6*10 (6558T > C and 6600G > T,
rs28399468), UMPS 638G >C (rs1801019), ABCB1 3545
C > T (rs1045642), ABCB1 1236 C > T (rs1128503), and
ABCB1 2677 G > T/A (rs2032582). Appropriate primers
were designed and polymerase chain reaction (PCR) was
performed using a GeneAmp PCR system 9700 thermal
cycler (Applied Biosystems, Foster City, CA, USA). Se-
quencing was carried out with an Automated ABI Prism
3100 Genetic Analyzer (Applied Biosystems). The pres-
ence of the CYP2A6 deletion allele (*4) was determined by
restriction fragment length polymorphism (RFLP) as de-
scribed in a previous study [11]. Positive (samples with
known genotype) and negative control (water) were in-
cluded to setting up sequencing reaction and each run of
PCR-RFLP.
Statistical analysis
We postulated that the pCR rate would be 20% or more,
and the rate of no interest was less than 10%. Using
Gehan-Simon’s two-stage phase II design implementing
a type I error of 0.05 and a power of 90%, 55 patients
would be accrued in stage 1, where study treatment was
futile if less than 3 patients obtained pCR [12]. If pCR
was observed in 4 or more patients in stage I, additional
54 patients would be enrolled. The primary endpoint
would be considered to meet if pCR was achieved in 17
or more patients in stage II. Therefore, a total of 109
evaluable patients were needed, and the target sample
size was 121 considering a drop-out rate of 10%.
The pCR rate was the proportion of patients who
achieved pCR out of those who underwent TME with
the 95% confidence interval (CI). RFS and OS at 3-years
and 5-years follow-up were estimated with the Kaplan-
Meier method and presented with the 95% CI. Safety
and pCR rate were assessed according to different dosing
schedules before and after protocol amendment and
compared using Chi square test or Fisher’s exact test.
The association of pharmacogenetic profile with clinical
outcome was assessed with the Cuzick’s test for trend
and log-rank test. As for ABCB1, analysis was done ac-
cording to each single-nucleotide polymorphisms (SNPs)
as well as the presence or absence of the reference allele
haplotype*1 (1236C, 3435C, and 2677G). Logistic regres-
sion analysis was used for adjustment of clinical vari-
ables in order to ascertain the clinical impact of the
pharmacogenetic profile. Statistical analysis was done
using STATA 14.0 (StataCorp LP, College Station, TX)
Results
Patients
From January 2009 to August 2012, 93 patients were en-
rolled. Enrollment was closed due to slow accrual in Sep-
tember 2012. Two patients withdrew consent before
treatment; thus, a total of 91 patients were included, as
shown in the study flowchart (Fig. 1). The baseline clinical
characteristics of 91 patients are described in Table 1.
Delivery of CRT
In the initial 23 (25.2%) patients who received UFT-E 400
mg/m2 7 days per week (7/week cohort), the dose inten-
sity was 92.6% of the intended dose, and the median cu-
mulative and daily dose during RT was 14,074 mg/m2 and
Fig. 1 The flowchart of the clinical trial and pharmacogenetic analysis.
Abbreviations:7/week, 7 days per week; 5/week, 5 days per week
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370 mg/m2/day, respectively. After protocol amendment,
68 patients were treated with a 5-days per week dosing
schedule (5/week cohort). The dose intensity was 98.9% of
the intended dose and the median cumulative and daily
dose was 11,073 mg/m2 and 291 mg/m2/day, respectively.
Eighty-seven (95.6%) patients completed the planned RT
schedule (50.4 Gy), while RT was interrupted in 4 patients
(2 from the 7/week cohort and 2 from the 5/week cohort)
due to grade 3 diarrhea. The mean of total RT dose was
50.1 Gy (range 41.4 – 50.4).
Surgical procedures and pathologic response
TME was performed in 90 patients; one patient who was
lost to follow-up after CRT eventually revisited our
clinic with progression of the primary tumor and distant
metastasis after 2 years. Eighty-three patients (92%)
underwent surgery between 7.5 and 13.7 weeks (median
7 weeks) after completion of CRT. Two of 90 patients
underwent synchronous resection of newly developed
liver metastases that were noted during preoperative re-
staging procedures. A sphincter-saving procedure (low
anterior resection or ultra-low anterior resection) was
performed in 84 patients (93.3%). Another 6 patients
underwent abdominoperineal resection. Laparoscopic
surgery was done in 70 (77.8%). The CRM was positive
(≤1mm) in 12 patients (13.3%), including 5 patients
whose CRM was involved by tumor.
Ten patients achieved pCR (11.1%, 95% CI 5.4 – 19.5),
3 (13.0%) from the 7/week cohort and 5 (7.3%) from the
5/week cohort (odds ratio 1.28, 95% CI 0.30 – 5.45, p =
0.733). Downstaging to ypStage 0 or I was seen in 35 pa-
tients (38.9%), and the distribution of downstaging was
similar between the two dosing cohorts; 9 (39.1%) from
the 7/week cohort, 26 (38.2%) from the 5/week cohort;
odds ratio 1.01, 95% CI 0.38 – 2.67, p = 0.978).
Toxicity during and after CRT
There were no grade 4 or 5 adverse events among the
91 patients who received at least one dose of the study
treatment, while 20 (22.0%) experienced grade 3 toxicity
during CRT. Grade 2 or more diarrhea occurred in 14
patients (15.4%), 8 from the 7/week cohort (34.8%) and
6 (8.8%) from the 5/week cohort (odds ratio 5.51, 95%
CI 1.66 – 18.29, p = 0.005). Stomatitis of grade 2 or
greater also occurred more frequently in the 7/week co-
hort (17.4%) than in the 5/week cohort (3%; odds ratio
6.95, 95% CI 1.18 – 40.9, p = 0.032). The overall distribu-
tion of each adverse event is listed in Table 2.
Acute postoperative complications within 30 days in-
cluded anastomosis leakage (n= 9), urinary retention (n = 7),
superficial incisional infection (n = 4), ileus (n = 4),
bleeding (n = 2), deep vein thrombosis (n = 1), and
pneumonia (n = 1). Among these complications, surgical
intervention under spinal or general anesthesia was
needed in 5 patients (3 for bleeding and 2 for anastomosis
leakage). Delayed surgical intervention 30 days or more
after TME was performed for anastomosis issues (leak,
stricture or skin tag) in 8 patients who had undergone a
sphincter-saving procedure; 5 underwent permanent
stoma formation.
Table 1 Baseline Characteristics (n = 91)
Variables N (%)








Well differentiated 30 (32.97)
Moderately differentiated 60 (65.93)








< 5 ng/ml 58 (65.91)
≥ 5 ng/ml 30 (34.09)
Distance from anal verge Median 6cm, range 1–8cm
Abbreviation: ECOG PS Eastern Cooperative Oncology Group performance
status, CEA carcinoembryonic antigen
Table 2 Adverse Events during Chemoradiation (n = 91)a
Grade 1 Grade 2 Grade 3
Leukopenia 24 (26.37%) 11 (12.09%) -
Neutropenia 1 (1.10%) 6 (6.59%) -
Anemia 33 (36.26%) 7 (7.69%) 2 (2.20%)
Thrombocytopenia 6 (6.59%) - -
Fatigue 17 (18.68%) - -
Anorexia 43 (47.25%) 4 (4.40%) 1 (1.10%)
Nausea 41 (45.05%) 1 (1.10%) -
Constipation 11 (12.09%) 1 (1.10%) -
Diarrhea 11 (12.09%) 4 (4.40%) 10 (10.99%)
Stomatitis 10 (10.99%) 5 (5.49%) 1 (1.10%)
Abdominal pain 35 (38.46%) 7 (7.69%) 2 (2.20%)
Anal pain 13 (14.29%) 5 (5.49%) -
aAdverse events were graded according to Common Terminology Criteria of
Adverse Events version 3.0. There were no grade 4 or 5 adverse events
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Post-operative treatment and survival
Eighty-six patients were administered adjuvant chemo-
therapy for 4 months. Two patients with metastatic dis-
ease, 1 with poor health status (due to poor glycemic
control and acute kidney injury) and 1 who was referred
to another hospital and lost to follow-up did not receive
adjuvant chemotherapy. Fluoropyrimidine monotherapy
(5-FU/LV or UFT-E/LV) was given in 74 (86%) and the
other 12 (14%) received FOLFOX-6.
As of November 2015, 9 events (8 distant metastases
and 1 local recurrence) had occurred; local curative
treatment (metastasectomy or salvage CRT) was admin-
istered in 4 out of 9 recurred patients and all of them
were alive without disease until the time of analysis. The
patient who was lost to follow-up and later showed pro-
gression was censored at the time of follow-up loss in
RFS analysis. With a median follow-up duration of 59.2
months (range 4.1 – 79.9), RFS at 3-years and 5-years
follow-up was 92.2% (95% CI 84.3 – 96.2) and 88.6%
(95% CI 79.9 – 93.7), respectively (Fig. 2A).
Six deaths occurred in patients who showed distant
metastases. Five died of rectal cancer progression, and
one patient with underlying emphysema died of pneu-
monia. OS at the 3-years and 5-years follow-up was
95.5% (95% CI 88.56 – 98.3%) and 94.2% (95% CI 86.57
– 97.55), respectively (Fig. 2B).
Clinical outcome according to genotype
Pharmacogenenetic samples were obtained from 91 pa-
tients including a patient who did not undergo surgery,
but 3 samples were insufficient for analysis (Fig. 1).
Allelic frequencies of CYP2A6*4, *7, *9 and *10 were
0.12, 0.15, 0.21, and 0.08. Allelic frequencies for UMPS
and ABCB1 were 0.31, 0.4, 0.36, and 0.71 for UMPS
G638C, ABCB1 C1236T, ABCB1 C3435T, and ABCB1
G2677T, respectively. No significant deviations from
Hardy-Weinberg equilibrium were seen except for ABCB1
G2677T (p = 0.001). The occurrence of toxicity according
to genotype is summarized in Table 3. As for CYP2A6, the
presence of variant alleles (*4, *7, *9, or *10) was
associated with leukopenia (p for tend = 0.022), but not
with neutropenia (p for trend = 0.161). Grade 2 or
greater stomatitis was only observed in variant homo-
zygotes of CYP2A6. The presence of the UMPS
G638C variant allele was associated with increased
risk of diarrhea (p for trend = 0.018). SNPs or the presence
of haplotype*1 of ABCB1 were not associated with any
type of toxicity.
Since the different dosing schedules used could have
affected the incidence of toxicity in this study, especially
diarrhea, the impact of polymorphisms on any toxicity ≥
grade 3 was tested again with adjustment for the dosing
schedule as well as age, sex and performance status
(Table 4); the CC genotype was the only genotype that
was associated with increased risk of grade 3 or more
toxicity. It was also significantly associated with grade 2
or greater diarrhea (odds ratio = 10.8, 95% CI 1.50 –
77.40, p = 0.018) after adjustment, while the GC geno-
type did not have a significant association with toxicity
compared to the GG genotype (odds ratio = 1.96, 95% CI
0.42 – 9.06, p = 0.389). Goodness-of-fit test suggested
the fit of recessive model for association of UMPS with
diarrhea (p = 0.111) was better than that of additive
model (p = 0.056).
Genotype and pCR rate analysis revealed that nonsignif-
icant relationship: there was a trend of increasing pCR
rate according to the number of UMPS G638C allele
(4.9% in GG, 15.8% in GC and 25.0% in CC) but not
statistically significant (p = 0.05). Neither was seen any
ordinal relationship of pCR rate with other genotypes:
CYP2A6 (p = 0.174), ABCB1 C1236T (p = 0.094), C3435T
(p = 0.949), ABCB1 G2677T (p = 0.406), and ABCB1
variant haplotype other than *1 (p = 0.302). RFS was not
also associated with any genotypes (data not shown).
Discussion
Our study indicated that preoperative CRT with UFT-E
was feasible in Korean patients with locally advanced
rectal cancer and that UMPS polymorphisms might be
predictive of UFT - based CRT toxicity.
Fig. 2 Relapse-free survival (a) and overall survival (b) of 91 patients who received study treatment
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The observed pCR rate of 11% is consistent with other
CRT studies based on 5-FU or capecitabine [2], although
it did not meet the primary endpoint, which was ex-
pected to be more than 20%. The endpoint was set based
on our pilot study, where the pCR rate was as high as
22% (95% CI 10.1–39.2), with 8 of 36 patients achieving
pCR. We can exclude the possibility of the pCR rate be-
ing affected by the number of sections or inter-observer
variation of the examining pathologists; surgical speci-
mens were examined according to consistent sectional
criteria by a single pathologist (HJC) in both the pilot
study and this phase II trial.
We postulated that an increased dose of UFT-E might
improve the pCR rate, but the results of this study were
insufficient to suggest such a dose-response relationship.
Furthermore, the pCR rate was similar between the 7/week
and 5/week cohorts. Intensifying chemotherapy with
oxaliplatin also did not seem to be a successful method of
improving pCR or disease-free survival in phase III trials
[13–16]. A dose of 400 mg/m2/day of UFT-E was chosen
based on phase I trial data indicating that continuous
dosing with 400 mg/m2/day administered as 3 divided
doses was tolerable [17], as well as our pilot study
showing a tolerable safety profile (grade 3 or 4


















w/w (n = 22) 0 (0%) 0 (0%) 1 (4.6%) 3 (13.6%) 1 (4.6%) 4 (18.2%) 0 (0%) 7 (31.8%)
w/v (n = 37) 4 (10.8%) 3 (8.1%) 4 (10.8%) 4 (10.8%) 4 (10.8%) 2 (5.4%) 0 (0%) 6 (16.2%)
v/v (n = 29) 6 (20.7%) 3 (10.3%) 4 (13.8%) 7 (24.1%) 0 (0%) 3 (10.3%) 6 (15.8%) 7 (24.1%)
P valuea 0.022† 0.161 0.291 0.269 0.398 0.428 0.012† 0.595
UMPS G638T
GG (n = 41) 5 (12.2%) 3 (7.3%) 6 (14.6%) 4 (9.8%) 1 (2.4%) 2 (4.9%) 3 (7.3%) 8 (19.5%)
GC (n = 39) 5 (12.8%) 3 (7.7%) 2 (5.1%) 6 (15.4%) 3 (7.7%) 5 (12.8%) 2 (5.1%) 7 (18.0%)
CC (n = 8) 0 (0.0%) 0 (0.0%) 1 (12.5%) 4 (50.0%) 1 (12.5%) 2 (25.0%) 1 (12.5%) 5 (62.5%)
P valuea 0.518 0.625 0.378 0.018† 0.183 0.067 0.557 0.078
ABCB1 C1236T
CC (n = 10) 1 (10.0%) 1 (10.0%) 1 (10.0%) 2 (20.0%) 0 (0.0%) 0 (0.0%) 0 (0%) 2 (20.0%)
CT (n = 49) 5 (10.2%) 2 (4.08%) 5 (10.2%) 7 (14.3%) 3 (6.1%) 5 (10.2%) 5 (10.2%) 12 (24.5%)
TT (n = 27) 4 (14.8%) 3 (11.1%) 3 (11.1%) 5 (18.5%) 2 (7.4%) 4 (14.8%) 1 (3.7%) 6 (22.2%)
P valuea 0.584 0.584 0.902 0.914 0.459 0.214 0.900 0.985
ABCB1 C3435T
CC (n = 35) 3 (8.6%) 2 (5.7%) 2 (5.7%) 4 (11.4%) 2 (5.7%) 4 (11.4%) 2 (5.7%) 9 (25.7%)
CT (n = 42) 6 (14.3%) 3 (7.1%) 6 (14.3%) 9 (21.4%) 2 (4.8%) 4 (9.5%) 4 (9.5%) 9 (21.4%)
TT (n = 11) 1 (9.1%) 1 (9.1%) 1 (9.1%) 1 (9.1%) 1 (9.1%) 1 (9.1%) 0 (0%) 2 (18.2%)
P valuea 0.717 0.689 0.447 0.723 0.804 0.776 0.819 0.559
ABCB1 G2677T
GG (n = 33) 3 (9.1%) 2 (6.1%) 2 (6.1%) 4 (12.1%) 2 (6.1%) 3 (9.1%) 2 (6.1%) 9 (27.3%)
GT (n = 26) 3 (11.5%) 2 (7.7%) 5 (19.2%) 5 (19.2%) 2 (7.7%) 3 (11.5%) 3 (11.5%) 5 (19.2%)
TT (n = 26) 3 (11.5%) 2 (7.7%) 2 (7.7%) 5 (19.2%) 1 (3.9%) 3 (11.5%) 1 (3.9%) 6 (23.1%)
p valuea 0.754 0.802 0.754 0.450 0.745 0.754 0.797 0.678
ABCB1 haplotype
*1/*1 (n = 7) 1 (14.29%) 1 (14.29%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (14.3%)
*1/v (n = 36) 3 (8.33%) 1 (2.78%) 5 (13.89%) 3 (8.33%) 4 (11.11%) 4 (11.11%) 4 (11.11%) 10 (27.8%)
v/v (n = 42) 5 (11.90%) 4 (9.52%) 4 (9.52%) 2 (4.76%) 5 (11.90%) 5 (11.90%) 2 (4.76%) 9 (21.4%)
P value 0.872 0.727 0.872 0.573 0.966 0.756 0.477 0.925
Abbreviations: CYP2A6 cytochrome P 2A6, w wild type allele, v variant allele, Abd abdominal, UMPS uridine monophosphate synthetase, ABCB1 ATP-binding
cassette B1
atest for trend by Cuzick’s test
†P value <0.05
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diarrhea in 12.8% of patients) with 400 mg/m2/day 7 days
per week. Eventually the dosing schedule was modified
due to toxicity; it was similar strategy in NSABP R-04 trial,
where the dosing days of capecitabine or 5-FU were
reduced from 7 to 5 days per week due to toxicity
concerns [18]. Grade 3 diarrhea developed in 26.1% of the
7/week cohort, whereas only 5.9% of the 5/week cohort
experienced it in our trial. The R-04 trial also showed that
the incidence of grade 3 to 5 diarrhea decreased from 16
to 7% after protocol amendment [18].
Nevertheless, our study showed that UFT-E 400 mg/
m2/day for 5 days per week with LV was feasible for
preoperative CRT for locally advanced rectal cancer. The
highest dose of UFT with RT in previous studies was
400 mg/m2, but it was not accompanied by LV, which
enhances the activity of 5-FU by promoting formation of
covalent bonds with thymidylate synthase, the target
enzyme of 5-FU [19].
Our study showed that UMPS polymorphisms might be
related to a higher incidence of diarrhea; an ordinal rela-
tionship between grade 2 or 3 diarrhea and the number of
G638C variant alleles was shown. These results could be
explained by metabolism of 5-FU; metabolites of 5-FU by
UMPS cause gastrointestinal toxicity via incorporation
into RNA (F-RNA) (20). UMPS G638C is a polymorphism
that reportedly confers enhanced enzymatic activity; grade
3–4 diarrhea in 5-FU or UFT/LV occurred more fre-
quently in Japanese patients with UMPS G538C genotype
(20, 21). It should be noted pharmacogenetic studies
on association of UMPS genotype and fluoropyrimi-
dines including ours were only exploratory analyses,
not confirmative biomarker study; there are still insuf-
ficient evidences on genotype-guided fluoropyrimidine
dosing in practice [20]. Furthermore, in this study, we
cannot rule out the possibility that these results were
confounded by other clinical variables, especially the
varied dosing schedule (7/week versus 5/week), although
the CC genotype was still a significant predictor of toxicity
after adjustment for the clinical variables including
dosing schedule.
Clinical activity of 5-FU or UFT was associated with
enhanced enzymatic activity or higher expression of
UMPS in several studies [21, 22], thus CC genotype har-
bor a possibility of resulting improved clinical outcome.
In our study, pCR rate tended to increase according to
the number of G638C variant allele without statistical
significance, while RFS was not related to the UMPS
polymorphism. Although this study did not have ad-
equate power to show the relationship of anti-tumor
activity of UFT-E and UMPS polymorphism, improved
pCR rate in UMPS 638 CC genotype (25%) could be
considered for further investigation.
Table 4 Multivariable analysis of risk for toxicity for patients carrying variant alleles
Genotype Diarrhea, ≥ Grade 2 Any grade 3 toxicity
Adjusted ORa 95% CI P value Adjusted ORa 95% CI P value
CYP2A6 w/w (n = 22) 1 (reference) 1 (reference)
w/v (n = 37) 0.69 0.12 – 3.89 0.671 0.29 0.07 – 1.19 0.086
v/v (n = 29) 1.87 0.38 – 9.29 0.443 0.52 0.13 – 2.03 0.343
UMPS G638T GG (n = 41) 1 (reference) 1 (reference)
GC (n = 39) 1.96 0.42 – 9.06 0.389 0.97 0.28 – 3.40 0.962
CC (n = 8) 10.76 1.50 – 77.39 0.018† 10.2 1.44 – 72.13 0.020†
ABCB1 C1236T CC (n = 10) 1 (reference) 1 (reference)
CT (n = 49) 0.43 0.06 – 3.13 0.406 0.99 0.16 – 5.97 0.990
TT (n = 27) 1.18 0.15 – 9.37 0.873 1.14 0.17 – 7.83 0.891
ABCB1 C3435T CC (n = 35) 1 (reference) 1 (reference)
CT (n = 42) 2.03 0.50 – 8.33 0.324 0.61 0.19 – 1.99 0.410
TT (n = 11) 1.10 0.10 – 12.19 0.940 0.82 0.13 – 5.11 0.836
ABCB1 G2677T GG (n = 33) 1 (reference) 1 (reference)
GT (n = 26) 1.45 0.30 – 6.92 0.645 0.44 0.11 – 1.77 0.248
TT (n = 26) 1.89 0.40 – 8.86 0.420 0.80 0.22 – 2.92 0.737
ABCB1 haplotype *1/*1 (n = 7) 1 (reference) 1 (reference)
*1/v (n = 36) 1.14 0.11 – 12.15 0.915 1.68 0.17 – 16.9 0.662
v/v (n = 42) 0.51 0.04 – 6.06 0.591 1.46 0.15 – 14.6 0.747
Abbreviations: OR odds ratio, CI confidence interval, CYP2A6 cytochrome P 2A6, w wild type allele, v variant allele, UMPS uridine monophosphate synthetase, ABCB1
ATP-binding cassette B1
aAdjusted for dosing schedule (7 days/week vs. 5 days/week), age, sex, and ECOG performance status (0 vs 1)
†P value <0.05
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Toxicity of tegafur-based drugs such as S-1 and UFT
occurs more frequently in Caucasian than in Asian pa-
tients, which was the rationale for the higher dose of
UFT-E used in our study. Differences in pharmacoki-
netic exposure to active metabolite (5-FU) did not ex-
plain this phenomenon, suggesting that a more
complicated mechanism might underly [6, 7]. Reduced
biotransformation of tegafur to 5-FU by the variant
CYP2A6, which is harbored more frequently by Asian
patients, was thought to be one of the causes of ethnic
differences, but such a relationship was not clear in
other studies with S-1-based regimen [23–25]. In
this study, leukopenia and stomatitis were more fre-
quent in variant genotypes, which were unexpected
findings. However, this is consistent with the case
report of a patient with the CYP2A6*9 allele who
showed severe UFT toxicity; the authors suggested
tegafur may be alternatively metabolized by cytosolic
enzymes as a mechanism of increased toxicity [26].
The impact of CYP2A6 genotype on tegafur-based
drugs needs to be clarified through well-designed
prospective trials.
The gene product of ABCB1, P-glycoprotein,
removes toxic metabolites from cells; hence, it can
also induce chemo-resistance in malignant cells. It is
extensively expressed in the gastrointestinal epithe-
lium and might control the uptake of oral agents
such as UFT from the gut [27]. Although fluoropyri-
midines are not a known substrate of ABCB1, ABCB1
expression is induced along with 5-FU resistance in
some cell lines [28], which suggests polymorphisms
concerning ABCB1 activity might be related to effi-
cacy of fluoropyrimidines. Otherwise, ABCB1 haplo-
type*1 was reportedly associated with capecitabine
toxicity compared to variant haplotypes [29]. How-
ever, a significant relationship between ABCB1 poly-
morphisms and clinical outcome was not observed in
this study.
This study has several limitations; we stopped enroll-
ment due to slow accrual, resulting in insufficient
statistical power for the pCR rate of CRT with UFT-E.
The association between toxicity profile and genotype
was not supported by the pharmacokinetic study. We
explored polymorphisms of 3 genes (UPMS, CYP2A6,
and ABCB1) which relate to metabolism and excretion
of tegafur or 5-FU, but other genes such as TYMS
and DPYD, which are well-known predictors of 5-FU
toxicity [30, 31], should have been tested. Our pilot
study with a higher dose of UFT-E should have been
done with a meticulous dose-escalating scheme. Dif-
ferent dosing schedule before and after protocol
amendment was a major confounding factor in the
interpretation of efficacy and safety outcomes, as well
as of the pharmacogenetic study.
Conclusions
UFT-E 400 mg/m2/day with LV for 5 days per week was
shown to be a feasible regimen when administered with
preoperative RT for patients with locally advanced rectal
cancer. A SNP of UMPS, G638C, was predictive of UFT-
E toxicity and could be studied further to explore
genotype-guided dosing.
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